title: [Preliminary study of HLA haplotype matched and T-cell undepleted allogeneic bone marrow transplantation for treatment of leukemia].
abstract: OBJECTIVE
  To explore the feasibility of allogeneic bone marrow transplantation (Allo-BMT) with graft from HLA haplotype matched related donor without T-cell depleted for the treatment of leukemia.
  
  
  METHODS
  Fifteen patients with leukemia received allo-BMT with grafts from HLA 2 or 3 antigen mismatched related donors. All patients were treated with standardized conditioning regimen consisting of high dose Ara-C, cyclophosphamide (CY) and total body irradiation (TBI). Donors were given G-CSF at 3 to 4 micrograms.kg-1.d-1 for seven days prior to marrow harvest. GVHD prophylaxis programme consisted of CsA, MTX, ATG and mycophenolate mofetial.
  
  
  RESULTS
  All patients established successful engraftment. The median days of granulocyte > 0.5 x 10(9)/L and platelet > 20 x 10(9)/L were 19(range 13-23) and 21 (range 16-32) days, respectively. Acute grade II-IV GVHD occurred in 5 of 15 patients (33.3%). Two of them were grade II gut aGVHD, 2 grade III gut aGVHD, and 1 grade IV gut and liver aGVHD. Chronic GVHDs were seen in 8 of 9 evaluable patients (88.9%) and none developed extensive cGVHD. The median follow-up duration was 395 (110-690) days. Six of fifteen patients died. Five of them died from transplantation related mortality and 1 from relapse. Nine patients were alive in a disease-free situation. Six of them survived more than one year.
  
  
  CONCLUSIONS
  The major histoincompatibility barriers in the haplotype matched related donor/recipient allo-BMT might be crossed by donor stimulated with G-CSF and combined GVHD prophylaxis program.
authors.affiliation: Research Centre for Hematology, General Hospital of Air Force PLA, Beijing 100036, China.
authors.forename: S
authors.initials: S
authors.lastname: Ji
authors.forename: H
authors.initials: H
authors.lastname: Chen
authors.forename: H
authors.initials: H
authors.lastname: Wang
mesh_terms: D000293:Adolescent; D000328:Adult; D016026:Bone Marrow Transplantation / Q000009:adverse effects; D002648:Child; D005260:Female; D006086:Graft vs Host Disease / Q000209:etiology; D006680:HLA Antigens / Q000235:genetics* / Q000276:immunology; D006239:Haplotypes; D006801:Humans; D007938:Leukemia / Q000276:immunology / Q000401:mortality / Q000628:therapy*; D008297:Male; D016019:Survival Analysis; D013601:T-Lymphocytes / Q000637:transplantation; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D006680:HLA Antigens